Clinical Trials Browser

Pancreatic Ductal Adenocarcinoma × ivosidenib × 1 year × Clear all

NCT05209074 2025-09-05

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Phase 1 Active not recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma